INO

Inovio is a pre-revenue, clinical-stage DNA-medicine company whose financials describe a binary science bet, not a business. FY2025 revenue was $65.3K (down 70% YoY) against a -$84.9M net loss and -$88.6M of operating cash burn — the 'revenue' is a rounding error, so the headline 1184x P/S and -130,000% net margin are meaningless except as confirmation there is no commercial engine. The MD&A is explicit: this is a 'clinical-stage biotechnology company' with a 'history of losses' and a 'lack of products that have received regulatory approval,' whose value rests entirely on whether lead candidate INO-3107 (for recurrent respiratory papillomatosis) and the CELLECTRA delivery platform survive trials where 'failure can occur at any time.'

The balance sheet turns that risk into a near-term funding cliff. Cash fell to $44.3M (down 32.7%) while the company burned $88.6M running operations — under a year, realistically ~6 months, of runway. Stockholders' equity collapsed 64.8% to $24.1M, liabilities/equity sits at 2.08x, and the $1.82B accumulated deficit shows how much capital this platform has consumed without an approval. Management lists 'the availability of funding' and 'the ability to manufacture our DNA medicine candidates' among its own primary risks — a tacit acknowledgment that another raise is required.